856 related articles for article (PubMed ID: 27773786)
21. Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD.
Kostikas K; Brindicci C; Patalano F
Curr Drug Targets; 2018; 19(16):1882-1896. PubMed ID: 29437007
[TBL] [Abstract][Full Text] [Related]
22. Mepolizumab for the prevention of chronic obstructive pulmonary disease exacerbations.
Fernandez Romero GA; Beros J; Criner G
Expert Rev Respir Med; 2019 Feb; 13(2):125-132. PubMed ID: 30570418
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-5 Antagonists Usher in a New Generation of Asthma Therapy.
Giannetti MP; Cardet JC
Curr Allergy Asthma Rep; 2016 Nov; 16(11):80. PubMed ID: 27796795
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibodies for asthma and chronic obstructive pulmonary disease.
Antoniu SA
Expert Opin Biol Ther; 2013 Feb; 13(2):257-68. PubMed ID: 23282002
[TBL] [Abstract][Full Text] [Related]
25. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.
Cazzola M; Matera MG; Levi-Schaffer F; Rogliani P
Expert Opin Drug Saf; 2018 Apr; 17(4):429-435. PubMed ID: 29486600
[TBL] [Abstract][Full Text] [Related]
26. Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects.
Máspero J
Ther Adv Respir Dis; 2017 Aug; 11(8):311-325. PubMed ID: 28683596
[TBL] [Abstract][Full Text] [Related]
27. Regulation of inflammatory cell function by corticosteroids.
Belvisi MG
Proc Am Thorac Soc; 2004; 1(3):207-14. PubMed ID: 16113436
[TBL] [Abstract][Full Text] [Related]
28. Asthma versus chronic obstructive pulmonary disease, the Dutch versus British hypothesis, and role of interleukin-5.
Chambliss JM; Sur S; Tripple JW
Curr Opin Allergy Clin Immunol; 2018 Feb; 18(1):26-31. PubMed ID: 29257776
[TBL] [Abstract][Full Text] [Related]
29. Mepolizumab for eosinophilic severe asthma: recent studies.
Robinson DS; Kariyawasam HH
Expert Opin Biol Ther; 2015 Jun; 15(6):909-14. PubMed ID: 25951938
[TBL] [Abstract][Full Text] [Related]
30. Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update.
Walsh GM
Expert Opin Biol Ther; 2020 Oct; 20(10):1237-1244. PubMed ID: 32529893
[TBL] [Abstract][Full Text] [Related]
31. The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges.
Barrecheguren M; Esquinas C; Miravitlles M
Curr Opin Pulm Med; 2015 Jan; 21(1):74-9. PubMed ID: 25405671
[TBL] [Abstract][Full Text] [Related]
32. Mepolizumab: First Global Approval.
Keating GM
Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
[TBL] [Abstract][Full Text] [Related]
33. Biological treatments for severe asthma: A major advance in asthma care.
Busse WW
Allergol Int; 2019 Apr; 68(2):158-166. PubMed ID: 30792118
[TBL] [Abstract][Full Text] [Related]
34. IgE and eosinophils as therapeutic targets in asthma.
Patel TR; Sur S
Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):42-49. PubMed ID: 27906698
[TBL] [Abstract][Full Text] [Related]
35. Primary care of asthma: new options for severe eosinophilic asthma.
Skolnik NS; Carnahan SP
Curr Med Res Opin; 2019 Jul; 35(7):1309-1318. PubMed ID: 30880484
[No Abstract] [Full Text] [Related]
36. Monoclonal antibodies for the treatment of refractory asthma.
Hambly N; Nair P
Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
[TBL] [Abstract][Full Text] [Related]
37. Exacerbations of Severe Asthma While on Anti-IL-5 Biologics.
Bhalla A; Zhao N; Rivas DD; Ho T; Perez de Llano L; Mukherjee M; Nair P
J Investig Allergol Clin Immunol; 2020; 30(5):307-316. PubMed ID: 32573459
[TBL] [Abstract][Full Text] [Related]
38. A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting.
Cameli P; Bergantini L; d'Alessandro M; Perruzza M; Cekorja B; Perillo F; Massa E; Ruzza A; Fossi A; Beltrami V; Sestini P; Bargagli E
Int Arch Allergy Immunol; 2020; 181(8):606-612. PubMed ID: 32516771
[TBL] [Abstract][Full Text] [Related]
39. Taking the red out of eosinophilic inflammation in COPD.
Bush RK
J Allergy Clin Immunol; 2020 Aug; 146(2):278-279. PubMed ID: 32502512
[No Abstract] [Full Text] [Related]
40. Mepolizumab for the treatment of severe eosinophilic asthma.
Poulakos MN; Cargill SM; Waineo MF; Wolford AL
Am J Health Syst Pharm; 2017 Jul; 74(13):963-969. PubMed ID: 28645995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
